About
CannRx develops proprietary science-based cannabis technologies. The company specializes in sleep and pain research, as well as on developing products for oncology support, Parkinson's disease, women's health, and recreational products for the sports industry. The company's ican.sleep is a proprietary formulation that targets sleep disorders. The product has undergone extensive in-vivo trials in predictive pharmaceutical models. CannRx has also performed extensive in-vivo testing of a pain management formulation, which has demonstrated significant and rapid relief of pain. CannRx's Vapor Capture Technology is an extraction technology designed specifically for the cannabis plant. The commercialized product provides a pre-activated, highly bio-available cannabis extract with a unique cannabinoid/terpene profile. The company is also creating a patented nanoparticle technology to solubilize cannabinoids and terpenes. The process inserts the important cannabis compounds into everyday proteins, resulting in highly soluble and stable nanoparticles. CannRx is a subsidiary of Izun Pharmaceuticals Corporation, a company in the boutique pharmaceutical area of botanical medicine.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of CannRx?
- According to startupim data, CannRx is currently inactive and ceased to operate in May 2022.
- What is CannRx's primary focus in cannabis technology?
- CannRx develops proprietary science-based cannabis technologies, specializing in sleep and pain research, and products for oncology support, Parkinson's disease, women's health, and the sports industry.
- What is CannRx's product 'ican.sleep' designed for?
- CannRx's ican.sleep is a proprietary formulation developed to target sleep disorders, which has undergone extensive in-vivo trials.
- What is CannRx's Vapor Capture Technology (VCT)?
- CannRx's Vapor Capture Technology (VCT) is an extraction technology specifically designed for the cannabis plant, providing a pre-activated, highly bio-available cannabis extract. A commercial model was announced in March 2018.
- What advanced technology is CannRx developing for cannabinoid delivery?
- CannRx is creating a patented nanoparticle technology to solubilize cannabinoids and terpenes by inserting them into everyday proteins, aiming for highly soluble and stable nanoparticles.
- When was CannRx founded?
- CannRx was founded in January 2017.
- What was a significant partnership for CannRx in March 2017?
- In March 2017, CannRx and iCAN:Israel-Cannabis announced a joint venture to market ican.sleep, an advanced sleep cannabis formulation.
- What is the relationship between CannRx and Izun Pharmaceuticals Corporation?
- CannRx is a subsidiary of Izun Pharmaceuticals Corporation, a company focused on botanical medicine.